139 related articles for article (PubMed ID: 36271265)
1. A Novel Bootstrapping Test for Analytical Biosimilarity.
Zahel T
AAPS J; 2022 Oct; 24(6):112. PubMed ID: 36271265
[TBL] [Abstract][Full Text] [Related]
2. On Statistical Approaches for Demonstrating Analytical Similarity in the Presence of Correlation.
Yang H; Novick S; Burdick RK
PDA J Pharm Sci Technol; 2016 11/12; 70(6):547-559. PubMed ID: 27325594
[TBL] [Abstract][Full Text] [Related]
3. Analytical Similarity Assessment in Biosimilar Studies.
Chow SC; Song F; Bai H
AAPS J; 2016 May; 18(3):670-7. PubMed ID: 26873509
[TBL] [Abstract][Full Text] [Related]
4. On the establishment of equivalence acceptance criterion in analytical similarity assessment.
Wang T; Chow SC
J Biopharm Stat; 2017; 27(2):206-212. PubMed ID: 28051920
[TBL] [Abstract][Full Text] [Related]
5. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
6. Statistical considerations regarding correlated lots in analytical biosimilar equivalence test.
Shen M; Wang T; Tsong Y
J Biopharm Stat; 2017; 27(2):213-219. PubMed ID: 27906604
[TBL] [Abstract][Full Text] [Related]
7. Development of statistical methods for analytical similarity assessment.
Tsong Y; Dong X; Shen M
J Biopharm Stat; 2017; 27(2):197-205. PubMed ID: 27977326
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
[TBL] [Abstract][Full Text] [Related]
9. Sample size requirement in analytical studies for similarity assessment.
Chow SC; Song F; Bai H
J Biopharm Stat; 2017; 27(2):233-238. PubMed ID: 27935446
[TBL] [Abstract][Full Text] [Related]
10. The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal.
Mielke J; Innerbichler F; Schiestl M; Ballarini NM; Jones B
AAPS J; 2018 Nov; 21(1):7. PubMed ID: 30483892
[TBL] [Abstract][Full Text] [Related]
11. Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity.
Zeng D; Pan J; Hu K; Chi E; Lin DY
J Biopharm Stat; 2018; 28(2):320-332. PubMed ID: 29173074
[TBL] [Abstract][Full Text] [Related]
12. Statistical Approaches to Assess Biosimilarity from Analytical Data.
Burdick R; Coffey T; Gutka H; Gratzl G; Conlon HD; Huang CT; Boyne M; Kuehne H
AAPS J; 2017 Jan; 19(1):4-14. PubMed ID: 27709452
[TBL] [Abstract][Full Text] [Related]
13. Adjustment for unbalanced sample size for analytical biosimilar equivalence assessment.
Dong XC; Weng YT; Tsong Y
J Biopharm Stat; 2017; 27(2):220-232. PubMed ID: 28060570
[TBL] [Abstract][Full Text] [Related]
14. On sample size requirement for analytical similarity assessment.
Zhao Y; Chang YW; Chow SC
J Biopharm Stat; 2018; 28(6):1143-1159. PubMed ID: 29513612
[TBL] [Abstract][Full Text] [Related]
15. Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms.
Nupur N; Joshi S; Gulliarme D; Rathore AS
Front Bioeng Biotechnol; 2022; 10():832059. PubMed ID: 35223794
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
[TBL] [Abstract][Full Text] [Related]
17. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products.
Kwon O; Joung J; Park Y; Kim CW; Hong SH
Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312
[TBL] [Abstract][Full Text] [Related]
18. The US approach to biosimilars: the long-awaited FDA approval pathway.
Calvo B; Zuñiga L
BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
[TBL] [Abstract][Full Text] [Related]
19. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
[TBL] [Abstract][Full Text] [Related]
20. An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment.
Wu K; Pan H; Li C; Zhao Q; Wang L; Xia J
PLoS One; 2018; 13(12):e0208354. PubMed ID: 30521581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]